1. Signaling Pathways
  2. GPCR/G Protein
  3. GPR35

GPR35

G Protein-Coupled Receptor 35

GPR35 is an orphan G protein-coupled receptor (GPCR) that is highly expressed in the gastrointestinal (GI) tract, predominantly in colon epithelial cells (CEC). Kynurenic acid, a metabolite of L-tryptophan, has been proposed to be the endogenous ligand of GPR3535. Upon kynurenic acid-mediated GPR35 activation, β-arrestin 2 translocates to the cell membrane to mediate GPR35 internalization, resulting in receptor desensitization. Single nucleotide polymorphisms of GPR35 have linked this receptor to inflammatory bowel disease and primary sclerosing cholangitis, suggesting a role in gastrointestinal inflammation. In addition, in conjunction with previous findings that link agonism of GPR35 with significant reduction in nociceptive pain, GPR35 has emerged as a potential effector of regulation of mechanical sensitivity and analgesia of the Ret tyrosine kinase, and as a receptor involved in the transmission of anti-inflammatory effects of aspirin– potentially through affecting leukocyte rolling, adhesion and extravasation.

GPR35 Related Products (25):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-131728
    GPR35 agonist 3
    Agonist 98.32%
    GPR35 agonist 3 is a synthetic GPR35 agonist with an EC50value of 1.4 μM. GPR35 agonist 3 can be used for the research of various diseases, such as gastric cancer, type 2 diabetes, cardiovascular diseases, immune system and peripheral nervous system.
    GPR35 agonist 3
  • HY-169303
    Gpr35 modulator 2
    Modulator
    Gpr35 modulator 2 (compound 52) is a GPR35 modulator. Gpr35 modulator 2 can be used for the study of a various GPR35-related disorders.
    Gpr35 modulator 2
  • HY-169302
    GPR35 activator-1
    Activator
    GPR35 activator-1 (example 5) is a potent GPR35 activator with a Ki of 0.08 nM for human GPR35.
    GPR35 activator-1
  • HY-106481
    Bufrolin
    Agonist
    Bufrolin is a Cromoglycate (histamine release inhibitor) analog and a high potency agonist of GPR35. Bufrolin promotes interactions between β-arrestin-2 and either human GPR35a or rat GPR35. Bufrolin also serves as antiallergic mast cell stabilizer and inhibit an anti-inflammatory response inducible by the internalization peptide. Bufrolin acts as an anti-inflammatory agent to be used in research of delivering pharmacol linked with internalization peptide.
    Bufrolin
  • HY-167706
    Diethyl-Lodoxamide
    Diethyl-Lodoxamide is a highly potent GPR35 agonist with potential to inhibit inflammatory bowel disease. Diethyl-Lodoxamide activates GPR35 in humans, mice and rats, showing similar EC50 values. Diethyl-Lodoxamide can alleviate the clinical symptoms of DSS-induced inflammatory bowel disease in mouse models, and the effect is better than the traditional drug 5-ASA. The pharmaceutical properties of Diethyl-Lodoxamide have been optimized to better meet the requirements of drug design.
    Diethyl-Lodoxamide